Tulathromycin A CAS NO.217500-96-4

introduction of tulathromycin c41h79n3o12

1. tulathromycin is a macrolide antibiotic used to treat bovine respiratory disease (brd) in cattle and swine respiratory disease in pigs.

2. tulathromycin a c41h79n3o12 is a triamilide antibiotic. exists as an equilibrium mixture of two isomeric forms, c41h79n3o12 tulathromycin a (90%) and b (10%)

packaging of tulathromycin c41h79n3o12

delivery of tulathromycin c41h79n3o12

prompt delivery after payment confirmed by air or by sea.

storage and shelf life of tulathromycin c41h79n3o12

specifications of tulathromycin c41h79n3o12

c41h79n3o12

china tulathromycin a 99%

217500-96-4 white powder

best price top quality tulathromycin c41h79n3o12

usp,bp,ep,cp

217500-96-4 tulathromycin a c41h79n3o12

product name	tulathromycin a c41h79n3o12
synonyms	(2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-13-[[2,6-dideoxy-3-c-methyl-3-o-methyl-4-c-[(propylamino)methyl]-a-l-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b-d-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one
molecular formula	c41h79n3o12
molecular weight	806.08
cas registry number	217500-96-4
molecular structure
density	1.17

functions of tulathromycin c41h79n3o12

• tulathromycin c41h79n3o12 is a macrolide antibiotic used to treat bovine respiratory disease (brd) in cattle and swine respiratory disease in pigs.

• clinical effectiveness of tulathromycin c41h79n3o12, a novel triamilide antimicrobial, for the control of respiratory disease in cattle at high risk for developing bovine respiratory disease.

the efficacy of tulathromycin c41h79n3o12 in decreasing the incidence of morbidity and mortality due to bovine respiratory disease (brd) in 1,239 high-risk cattle was investigated at four us feedlots. calves not exhibiting clinical signs of brd received one of three treatments administered subcutaneously in the neck: physiologic saline at 0.02 ml/kg, tulathromycin c41h79n3o12 at 2.5 mg/kg, or tilmicosin at 10 mg/kg. each treatment group consisted of 413 calves. calves with clinical signs of brd and rectal temperatures of 104 degrees f or higher on days 1 through 14 were considered treatment failures (brd morbidity). nasopharyngeal swabs from saline-treated morbidities were submitted for isolation and identification of brd organisms. respiratory disease morbidity was highest in calves treated with saline and significantly (p < or = .0001) lower in calves administered tulathromycin c41h79n3o12 or tilmicosin. morbidity from brd was significantly (p < or = .0001) higher in calves treated with tilmicosin than in calves treated with tulathromycin c41h79n3o12. under conditions of this study, tulathromycin c41h79n3o12, given to calves at high risk of developing brd, was significantly more effective in reducing brd morbidity when compared to both saline- and tilmicosin-treated calves.

coa of tulathromycin a c41h79n3o12

c41h79n3o12

china tulathromycin a 99%

217500-96-4 white powder

best price top quality tulathromycin c41h79n3o12

usp,bp,ep,cp